Cargando…

A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score

The Mayo Clinical Score is used in clinical trials to describe the clinical status of patients with ulcerative colitis (UC). It comprises four subscores: rectal bleeding (RB), stool frequency (SF), physician's global assessment, and endoscopy (ENDO). According to recent US Food and Drug Adminis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moein, Anita, Langenhorst, Jurgen, Plan, Elodie L., Jin, Jin Y., Kågedal, Matts, Kassir, Nastya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651636/ https://www.ncbi.nlm.nih.gov/pubmed/37718498 http://dx.doi.org/10.1111/cts.13632

Ejemplares similares

Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
por: Kassir, Nastya, et al.
Publicado: (2022)

A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis
por: Kawakatsu, Sonoko, et al.
Publicado: (2021)

Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program
por: Sandborn, William J., et al.
Publicado: (2022)

Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
por: Moein, Anita, et al.
Publicado: (2022)

Comparison of the Mayo Endoscopy Score and the Ulcerative Colitis Endoscopy Index of Severity and the Ulcerative Colitis Colonoscopy Index of Severity
por: Belvis Jiménez, María, et al.
Publicado: (2021)

Full, Partial, and Modified Permutations of the Mayo Score: Characterizing Clinical and Patient-Reported Outcomes in Ulcerative Colitis Patients
por: Naegeli, April N, et al.
Publicado: (2021)

Relationship between Mayo endoscopic score and histological scores in ulcerative colitis: A prospective study
por: Shah, Jimil, et al.
Publicado: (2019)

Real-life evaluation of histologic scores for Ulcerative Colitis in remission
por: Arkteg, Christian Børde, et al.
Publicado: (2021)

How disease extent can be included in the endoscopic activity index of ulcerative colitis: the panMayo score, a promising scoring system
por: Bálint, Anita, et al.
Publicado: (2018)

Correlation of Biomarkers with Endoscopic Score: Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in Patients with Ulcerative Colitis in Remission
por: Pop, Corina Silvia, et al.
Publicado: (2020)

Development and validation of a deep learning-based approach to predict the Mayo endoscopic score of ulcerative colitis
por: Qi, Jing, et al.
Publicado: (2023)

Population Pharmacokinetics of Tenecteplase in Patients With Acute Myocardial Infarction and Application to Patients With Acute Ischemic Stroke
por: Tang, Fei, et al.
Publicado: (2022)

Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule‐1 (MAdCAM‐1), in Patients With Ulcerative Colitis or Crohn's Disease
por: Wang, Yi, et al.
Publicado: (2020)

Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis
por: Viscido, Angelo, et al.
Publicado: (2022)

Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Score (MES) in guiding the need for colectomy in patients with acute severe colitis
por: Xie, Tingbin, et al.
Publicado: (2018)

Time-adjusted average Mayo endoscopic score predicts the risk of disease extent progression in distal ulcerative colitis patients
por: Wan, Jian, et al.
Publicado: (2022)

Therapeutic Potential of Proanthocyanidins in Ulcerative Colitis in Remission
por: Głąbska, Dominika, et al.
Publicado: (2020)

Transcriptional Signatures That Define Ulcerative Colitis in Remission
por: Fenton, Christopher G, et al.
Publicado: (2020)

Impact of the Concomitant Use of Immunomodulator and a Lower Week 8 Partial Mayo Score on the Persistence of Adalimumab in Refractory Ulcerative Colitis
por: Kumei, Shinsuke, et al.
Publicado: (2021)

Remission of ulcerative colitis flare-up induced by nivolumab
por: Iwamoto, Maho, et al.
Publicado: (2020)

A167 HISTOLOGICAL REMISSION PLACEBO RATES IN ULCERATIVE COLITIS TRIALS: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Youssef, M, et al.
Publicado: (2023)

Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program
por: Dubinsky, Marla C, et al.
Publicado: (2022)

Detecting placebo and drug effects on Parkinson's disease symptoms by longitudinal item‐score models
por: Chen, Chao, et al.
Publicado: (2021)

Deep learning model for distinguishing Mayo endoscopic subscore 0 and 1 in patients with ulcerative colitis
por: Kim, Ji Eun, et al.
Publicado: (2023)

Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis
por: Goll, Rasmus, et al.
Publicado: (2019)

The Mayo Endoscopic Score Is a Novel Predictive Indicator for Malignant Transformation in Ulcerative Colitis: A Long-Term Follow-Up Multicenter Study
por: Xu, Weimin, et al.
Publicado: (2022)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019)

Analysis of Endoscopic Evaluation Reliability for Ulcerative Colitis in Histological Remission
por: Kanazawa, Mimari, et al.
Publicado: (2021)

Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis
por: Lee, Sun-Ho, et al.
Publicado: (2017)

Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis
por: Haga, Keiichi, et al.
Publicado: (2022)

Association of endoscopic and histological remission with clinical course in patients of ulcerative colitis
por: Narang, Vikram, et al.
Publicado: (2018)

Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2018)

Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis
por: Paschos, Paschalis, et al.
Publicado: (2018)

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
por: Feagan, Brian G, et al.
Publicado: (2019)

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
por: Naganuma, Makoto, et al.
Publicado: (2021)

Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis
por: Gonzalez-Vivo, Maria, et al.
Publicado: (2022)

Increased modified DUBLIN scores are associated with serious ulcerative colitis and treatment failure
por: Liu, Lupeng, et al.
Publicado: (2022)

Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore
por: Lee, Scott D., et al.
Publicado: (2023)

Analysis of Longitudinal‐Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models
por: Lu, Tong, et al.
Publicado: (2020)

Appendiceal Orifice Inflammation Is Associated with Lower Rate of Complete Endoscopic Remission in Patients with Ulcerative Colitis
por: Oh, Chang Kyo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jmgu9f85tn4f6quc8isoop80e6